The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Allenex AB's share price is £0.00.
Allenex AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2016 was £0.09. Hence, Allenex AB's PS Ratio for today is 0.00.
The historical rank and industry rank for Allenex AB's PS Ratio or its related term are showing as below:
LTS:0O9J'
s PS Ratio Range Over the Past 10 Years
Min: 0.64 Med: 2.36 Max: 11.56
Current: 2.22
During the past 11 years, Allenex AB's highest PS Ratio was 11.56. The lowest was 0.64. And the median was 2.36.
LTS:0O9J's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.03
vs LTS:0O9J: 2.22
Allenex AB revenue has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Allenex AB was 7.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -19.60% per year.
During the past 11 years, Allenex AB's highest 3-Year average Revenue per Share Growth Rate was 6.10% per year. The lowest was 0.00% per year. And the median was -41.35% per year.
Back to Basics: PS Ratio
Allenex AB PS Ratio Historical Data
The historical data trend for Allenex AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Allenex AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allenex AB's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allenex AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Allenex AB's PS Ratio falls into.
Allenex AB PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Allenex AB's Share Price of today is £0.00. Allenex AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Allenex AB PS Ratio Related Terms
Thank you for viewing the detailed overview of Allenex AB's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Allenex AB creates life-science companies in collaboration with innovators. The process requires identifying ideas with commercial potential, and then contributing entrepreneurship and capital. Its portfolio consists of twelve companies, four in drug development and biotechnology, and eight in diagnostics and medical technologies. The company portfolio accounts for more than 50 different projects, some nearing the commercialization phase while others are already selling their products of services, in a wide range of therapeutic areas- from HIV and cancer to eye disease and allergies. Its Drug Development and Biotechnology business area is comprised of four companies: Anamar Medical, IMED, Novahep, and Recopharma. Anamar Medical develops drugs and biomarkers for diagnosing and monitoring/predicting chronic joint diseases such as rheumatoid arthritis and osteoarthritis, with five drug candidates' two biomarkets, and two commercial biomarkers. IMED develops human monoclonal antibodies (MAB) that induce or block natural cell death or apoptosis, and intending to develop antibodies for major therapeutic areas, including HIV, cancer, and transplantation. Novahep, in collaboration with the Karolinska Institute, aims to differentiate cell lines of fetal liver stem cells, which can then be used in the transplantation sector. Recopharma develops mucins for the vaccine market and antimicrobial substances to combat bacteria and viruses that may cause eye infection, influenza, and the Norwalk virus. The companies in the Diagnostics and Medical Technology business area include Absorber, Bioresonator, Biovator, Likvor, Olerup, Olerup SSP, Oncolog, Ortoviva, and Pharmacolog. These companies develop products such as the XM-ONE transplantation test, biomedical sensors, allergic reaction testing technology for the pharmaceutical, cosmetic and chemical industries, a diagnostic instrument to measure cerebrospinal fluid pressure (CSF), tools to facilitate the insertion of artificial discs in spinal surgery, and systems to control the content and concentration of liquid pharmaceutical drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0O9J has been successfully added to your 